安进

Amgen's 15min Chart Indicates Overbought RSI and Narrowing Bollinger Bands

Amgen: Argus Research raises PT to $400 from $360, maintains Buy rating.

Amgen: Guggenheim Raises PT to $347, Maintains Neutral Rating

Amgen's 15min chart signals Bollinger Bands Narrowing and KDJ Death Cross.

Amgen

Amgen's Earnings Beat Expectations Despite FDA Request to Pull Tavneos from Market

Catalyst<ul> <li>Small, Medium, and Large order-sized fund flows show positive net inflow trends, indicating growing institutional or retail investor interest in AMGN.</li></ul>Risk<ul> <li>Technical signals show a weak market state with four bearish indicators and no bullish ones, highlighting a higher risk of decline.</li> <li>Analyst ratings are inconsistent, with five Neutral ratings versus three Buy or Strong Buy, reflecting mixed institutional confidence.</li></ul>

Key Factors

Amgen (AMGN) surged 13.51% over three days, driven by institutional buying and elevated trading volume.Amgen's Q4 2025 earnings and revenue beat consensus estimates, fueled by strong performance in its obesity-related pipeline.The FDA requested the withdrawal of Amgen's drug Tavneos due to liver health risks and clinical trial concerns.Argus Research raised its price target for Amgen to $400 from $360, maintaining a Buy rating based on strong earnings and product momentum.Amgen's stock closed near its 52-week high on February 6, 2026, following record product sales and strong earnings.

AMGN News